Trametinib Dimethyl Sulfoxide Patent Expiration
Trametinib Dimethyl Sulfoxide is used for treating various cancers, including melanoma, anaplastic thyroid cancer, non-small cell lung cancer, and low-grade glioma, in combination with dabrafenib. It was first introduced by Novartis Pharmaceuticals Corp
Trametinib Dimethyl Sulfoxide Patents
Given below is the list of patents protecting Trametinib Dimethyl Sulfoxide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mekinist |
US10869869 (Pediatric) | Method of adjuvant cancer treatment | Feb 28, 2034 | Novartis |
| Mekinist | US10869869 | Method of adjuvant cancer treatment | Aug 30, 2033 | Novartis |
| Mekinist |
US8580304 (Pediatric) | Pharmaceutical composition | Jul 28, 2032 | Novartis |
| Mekinist |
US9155706 (Pediatric) | Pharmaceutical composition | Jul 28, 2032 | Novartis |
| Mekinist |
US9271941 (Pediatric) | Pharmaceutical composition | Jul 28, 2032 | Novartis |
| Mekinist |
US9399021 (Pediatric) | Pharmaceutical composition | Jul 28, 2032 | Novartis |
| Mekinist | US8580304 | Pharmaceutical composition | Jan 28, 2032 | Novartis |
| Mekinist | US9155706 | Pharmaceutical composition | Jan 28, 2032 | Novartis |
| Mekinist | US9271941 | Pharmaceutical composition | Jan 28, 2032 | Novartis |
| Mekinist | US9399021 | Pharmaceutical composition | Jan 28, 2032 | Novartis |
| Mekinist |
US8703781 (Pediatric) | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | Apr 15, 2031 | Novartis |
| Mekinist |
US8952018 (Pediatric) | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | Apr 15, 2031 | Novartis |
| Mekinist | US8703781 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | Oct 15, 2030 | Novartis |
| Mekinist | US8952018 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | Oct 15, 2030 | Novartis |
| Mekinist |
US7378423 (Pediatric) | Pyrimidine compound and medical use thereof | Nov 29, 2027 | Novartis |
| Mekinist | US7378423 | Pyrimidine compound and medical use thereof | May 29, 2027 | Novartis |
| Mekinist |
US8835443 (Pediatric) | Pyrimidine compound and medical use thereof | Dec 10, 2025 | Novartis |
| Mekinist | US8835443 | Pyrimidine compound and medical use thereof | Jun 10, 2025 | Novartis |
Trametinib Dimethyl Sulfoxide's Family Patents
Explore Our Curated Drug Screens
Trametinib Dimethyl Sulfoxide Generic API Manufacturers
Several generic applications have been filed for Trametinib Dimethyl Sulfoxide.
Given below is the list of companies who have filed for Trametinib Dimethyl Sulfoxide generic, along with the locations of their manufacturing plants worldwide.
1. HIKMA
Hikma Pharmaceuticals International Ltd has filed for 2 different strengths of generic version for Trametinib Dimethyl Sulfoxide. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.5MG | tablet | Discontinued | ORAL | N/A | Aug 6, 2024 |
| EQ 2MG | tablet | Discontinued | ORAL | N/A | Aug 6, 2024 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||